Argenx price target raised to $566 from $460 at Baird

Baird raised the firm’s price target on Argenx to $566 from $460 and keeps an Outperform rating on the shares. The firm believes the data is strong for CIDP and adds convincing support that Vyvgart is a pipeline-in-a-product that will likely go on to be approved for a variety of indications, at least for other neuromuscular indications if not beyond. Baird also believes the major driver of the stock over the coming months will be speculation around ARGX as a takeout candidate.